Brainsway Ltd.(BWAY)

Description: Brainsway is a commercial stage medical device company focused on the development and sale of non-invasive neuromodulation products using the Company’s proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) technology for the treatment of major depressive disorder (MDD) and obsessive-compulsive disorder (OCD), for which Brainsway received marketing authorization from the U.S. Food and Drug Administration (FDA) in 2013 (for MDD) and in August 2018 (for OCD). Brainsway is currently conducting clinical trials of Deep TMS in other psychiatric, neurological and addiction disorders, including smoking cessation and post-traumatic stress disorder, and is planning trials for opioid addiction, fatigue in multiple sclerosis (MS) and post-stroke rehabilitation.

---

Keywords: Neuroscience Mental Health Multiple Sclerosis Smoking Stroke Psychiatry Opioids FDA Smoking Cessation Major Depressive Disorder Neurophysiology Neurotechnology Addiction Post Traumatic Stress Disorder Depressive Disorder Neuromodulation Neuropsychology Treatment Of Depression Treatment Of Major Depressive Disorder Transcranial Magnetic Stimulation Obsessive Compulsive Disorder Brainsway Neuromodulation Products Non Invasive Neuromodulation Products

---

Home Page: www.brainsway.com

BWAY Technical Analysis

Bynet Building
Jerusalem, 9777518
Israel
Phone: 972 2 582 4030

---

Officers

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)